Contract Research & Services
Clinical Trials

OncoMed doses first patient in phase 1b trial of brontictuzumab

Published 23 January 2017

OncoMed Pharmaceuticals has dosed the first patient in a Phase 1b clinical trial of brontictuzumab (anti-Notch1, OMP-52M51) plus chemotherapy in metastatic colorectal cancer patients.

The Phase 1b trial is intended to determine the maximum-tolerated dose of brontictuzumab in combination with trifluridine/tipiracil (Lonsurf).  The Phase 1b trial is designed to assess safety, preliminary efficacy and immunogenicity, as well as predictive and pharmacodynamics biomarkers. 

Metastatic colorectal cancer patients who have received at least two prior lines of therapy will be enrolled in the dose-escalation portion of the trial, and once a maximum tolerated dose is identified, additional patients whose tumors test high for the activated form of Notch1 will be enrolled in an expansion cohort.

OncoMed clinical research and development senior vice president Robert Stagg, Pharm.D. said: “Brontictuzumab targets Notch1, a key receptor in the Notch pathway, and preclinical data suggest that elevated Notch1 gene expression appears to be an oncogenic driver in a number of tumor types, including colorectal cancer. 

“In this Phase 1b trial, we expect to determine the safety and optimal therapeutic index of brontictuzumab in combination with chemotherapy, assess preliminary efficacy and explore the correlation of biomarker status and anti-tumor responses.”

About Brontictuzumab

Brontictuzumab (anti-Notch1, OMP-52M51) blocks signaling of Notch, an important cancer stem cell pathway implicated in chemoresistance, tumor angiogenesis and stem cell self-renewal, proliferation and differentiation. 

Notch1 signaling is prevalent in several solid tumor types, including certain breast, esophageal, colorectal, gastric, pancreatic and small cell lung cancers, as well as adenoid cystic carcinoma and cholangiocarcinoma. 

Single-agent anti-tumor activity was observed in OncoMed’s Phase 1a dose escalation study of brontictuzumab in patients with certain advanced solid tumors, particularly in biomarker-defined patients whose tumors tested positive for overexpression of the activated form of Notch1.  Brontictuzumab was generally well tolerated, with the most common adverse event being manageable diarrhea.

OncoMed retains the worldwide rights to develop brontictuzumab.

Source: Company Press Release